Arbutus Biopharma Corp (LTS:0SGC)
$ 3.8501 -0.0293 (-0.76%) Market Cap: 747.58 Mil Enterprise Value: 607.19 Mil PE Ratio: 0 PB Ratio: 5.95 GF Score: 43/100

Q2 2022 Arbutus Biopharma Corp Earnings Call Transcript

Aug 04, 2022 / 12:45PM GMT
Release Date Price: $2.45 (+8.28%)
Operator

Good morning. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Arbutus Biopharma 2022 Second Quarter Financial Results and Corporate Update. (Operator Instructions)

Thank you, Ms. Lisa Caperelli, Vice President of Investor Relations. You may begin your conference.

Lisa M. Caperelli
Arbutus Biopharma Corporation - VP of IR

Thank you, Abby. Good morning, everyone, and thank you for joining our second quarter 2022 financial results and corporate update call. Joining me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Bill will begin with a corporate update, followed by Dave Hastings who will provide a review of the company's second quarter 2022 financial results. After opening remarks, we will open the call up for Q&A. Gaston Picchio and Mike Sofia will be available to address clinical and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot